Comprehensive genomic profiling of combined small cell lung cancer.
Combined small cell lung cancer (CSCLC)
comprehensive genomic profiling
small cell lung cancer (SCLC)
targeted gene sequencing
Journal
Translational lung cancer research
ISSN: 2218-6751
Titre abrégé: Transl Lung Cancer Res
Pays: China
ID NLM: 101646875
Informations de publication
Date de publication:
Feb 2021
Feb 2021
Historique:
entrez:
15
3
2021
pubmed:
16
3
2021
medline:
16
3
2021
Statut:
ppublish
Résumé
Combined small cell lung cancer (CSCLC) is an uncommon and heterogeneous subtype of small cell lung cancer (SCLC). However, there is limited data concerning the different molecular changes and clinical features in CSCLC compared to pure SCLC. The clinical and pathological characteristics of pure SCLC and CSCLC patients were analyzed. Immunohistochemistry and microdissection were performed to isolate the CSCLC components. Further molecular analysis was carried out by next-generation sequencing (NGS) in 12 CSCLC and 30 pure SCLC. There were no significant differences in clinical features between CSCLC and pure SCLC. Overall survival (OS) of CSCLC patients was worse than pure SCLC (P=0.005). NGS results indicated that There were no significant differences in terms of clinical features between CSCLC and pure SCLC. However, the prognosis for CSCLC was worse than pure SCLC. NGS analysis suggested that CSCLC components might derive from the same pluripotent single clone with common initial molecular alterations and subsequent acquisitions of other genetic mutations.
Sections du résumé
BACKGROUND
BACKGROUND
Combined small cell lung cancer (CSCLC) is an uncommon and heterogeneous subtype of small cell lung cancer (SCLC). However, there is limited data concerning the different molecular changes and clinical features in CSCLC compared to pure SCLC.
METHODS
METHODS
The clinical and pathological characteristics of pure SCLC and CSCLC patients were analyzed. Immunohistochemistry and microdissection were performed to isolate the CSCLC components. Further molecular analysis was carried out by next-generation sequencing (NGS) in 12 CSCLC and 30 pure SCLC.
RESULTS
RESULTS
There were no significant differences in clinical features between CSCLC and pure SCLC. Overall survival (OS) of CSCLC patients was worse than pure SCLC (P=0.005). NGS results indicated that
CONCLUSIONS
CONCLUSIONS
There were no significant differences in terms of clinical features between CSCLC and pure SCLC. However, the prognosis for CSCLC was worse than pure SCLC. NGS analysis suggested that CSCLC components might derive from the same pluripotent single clone with common initial molecular alterations and subsequent acquisitions of other genetic mutations.
Identifiants
pubmed: 33718010
doi: 10.21037/tlcr-20-1099
pii: tlcr-10-02-636
pmc: PMC7947408
doi:
Types de publication
Journal Article
Langues
eng
Pagination
636-650Informations de copyright
2021 Translational Lung Cancer Research. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037tlcr-20-1099). Dr. JM serves as an unpaid editorial board member of Translational Lung Cancer Research from Aug 2019 to Aug 2021. The authors have no other conflicts of interest to declare.
Références
Nat Genet. 2012 Oct;44(10):1111-6
pubmed: 22941189
Am J Surg Pathol. 2002 Sep;26(9):1184-97
pubmed: 12218575
Transl Lung Cancer Res. 2016 Feb;5(1):51-70
pubmed: 26958493
Nature. 2014 Mar 13;507(7491):190-4
pubmed: 24499815
Lung Cancer. 2016 Aug;98:33-42
pubmed: 27393504
Cancer Sci. 2007 Nov;98(11):1714-9
pubmed: 17784875
N Engl J Med. 2018 Dec 6;379(23):2220-2229
pubmed: 30280641
Br J Cancer. 1997;75(1):79-86
pubmed: 9000602
Aging (Albany NY). 2020 Jan 20;12(2):1285-1303
pubmed: 31959735
J Thorac Oncol. 2014 Jun;9(6):892-6
pubmed: 24828667
Nat Genet. 2012 Oct;44(10):1074-5
pubmed: 23011222
Clin Cancer Res. 1999 Jan;5(1):17-23
pubmed: 9918198
Cancer Discov. 2012 Sep;2(9):798-811
pubmed: 22961666
J Thorac Oncol. 2009 Feb;4(2):227-39
pubmed: 19179901
Science. 2000 Jun 2;288(5471):1660-3
pubmed: 10834848
Hum Pathol. 2003 Nov;34(11):1178-84
pubmed: 14652820
Cancer Cell. 2011 Jun 14;19(6):754-64
pubmed: 21665149
Oncotarget. 2016 Aug 30;7(35):56200-56208
pubmed: 27621042
Clin Lung Cancer. 2013 Mar;14(2):113-9
pubmed: 23010092
Cancer Cell. 2016 Oct 10;30(4):519-532
pubmed: 27728803
J Thorac Oncol. 2017 Nov;12(11):1673-1678
pubmed: 28843361
J Thorac Oncol. 2019 Dec;14(12):e276-e279
pubmed: 31757380
CA Cancer J Clin. 2016 Mar-Apr;66(2):115-32
pubmed: 26808342
J Thorac Oncol. 2016 May;11(5):639-650
pubmed: 26940528
Jpn J Clin Oncol. 2019 Dec 27;49(12):1143-1150
pubmed: 31612912
Nat Genet. 2009 Nov;41(11):1238-42
pubmed: 19801978
J Clin Oncol. 2006 Oct 1;24(28):4539-44
pubmed: 17008692
Lancet. 2019 Nov 23;394(10212):1929-1939
pubmed: 31590988
Cancer Cell. 2011 Feb 15;19(2):244-56
pubmed: 21316603
Nat Commun. 2018 Mar 1;9(1):894
pubmed: 29497050
N Engl J Med. 2016 May 12;374(19):1864-73
pubmed: 27168435
Am J Clin Pathol. 2009 Mar;131(3):376-82
pubmed: 19228643
Nature. 2015 Aug 6;524(7563):47-53
pubmed: 26168399
Kyobu Geka. 2006 Jun;59(6):497-500
pubmed: 16780072
J Thorac Oncol. 2009 Jan;4(1):37-43
pubmed: 19096304
J Thorac Oncol. 2019 Sep;14(9):1640-1650
pubmed: 31125737
Int J Cancer. 2016 Feb 15;138(4):927-38
pubmed: 26340530
Lung Cancer. 2017 Dec;114:12-22
pubmed: 29173760
PLoS Pathog. 2011 Mar;7(3):e1002014
pubmed: 21483485
Chest. 1986 May;89(5):699-704
pubmed: 3009096
J Thorac Oncol. 2018 Feb;13(2):237-245
pubmed: 29101056
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Lung Cancer. 2019 Mar;129:107-109
pubmed: 30591232
Cancer Cell. 2018 May 14;33(5):853-861.e4
pubmed: 29731394
Lancet Oncol. 2015 Apr;16(4):e165-72
pubmed: 25846096
Clin Cancer Res. 2019 Aug 1;25(15):4701-4711
pubmed: 31068370
PLoS Med. 2016 Dec 13;13(12):e1002193
pubmed: 27959926